The Subacute Cutaneous Lupus Erythematosus (SCLE) drugs in development market research report provides comprehensive information on the therapeutics under development for Subacute Cutaneous Lupus Erythematosus (SCLE), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Subacute Cutaneous Lupus Erythematosus (SCLE). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Subacute Cutaneous Lupus Erythematosus (SCLE) and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Subacute Cutaneous Lupus Erythematosus (SCLE) by six companies/universities/institutes. The top development phase for Subacute Cutaneous Lupus Erythematosus (SCLE) is phase ii with three drugs in that stage. The Subacute Cutaneous Lupus Erythematosus (SCLE) pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Subacute Cutaneous Lupus Erythematosus (SCLE) pipeline products market are: Bristol-Myers Squibb, GSK and Merck.
The key targets in the Subacute Cutaneous Lupus Erythematosus (SCLE) pipeline products market include Non Receptor Tyrosine Protein Kinase TYK2, Toll Like Receptor 8, and Toll-Llike Receptor 7.
The key mechanisms of action in the Subacute Cutaneous Lupus Erythematosus (SCLE) pipeline product include Interferon Alpha/Beta Receptor 1 Antagonist with one drug in Phase III. The Subacute Cutaneous Lupus Erythematosus (SCLE) pipeline products include four routes of administration with the top ROA being Subcutaneous and three key molecule types in the Subacute Cutaneous Lupus Erythematosus (SCLE) pipeline products market including Monoclonal Antibody, and Small Molecule.
Subacute Cutaneous Lupus Erythematosus (SCLE) overview
Subacute cutaneous lupus (SCLE) is an autoimmune disorder, that occurs when the immune system attacks itself. This is a subtype of CLE presenting as symmetric, non-scarring photosensitive erythematous rash usually over syn-exposed areas like face, neck, arms, upper back, and shoulders that causes skin rashes or lesions (sores).
For a complete picture of Subacute Cutaneous Lupus Erythematosus (SCLE)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
